Systematic Financial Management LP Sells 37,504 Shares of Enhabit, Inc. (NYSE:EHAB)

Systematic Financial Management LP reduced its stake in shares of Enhabit, Inc. (NYSE:EHAB) by 2.2% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,638,964 shares of the company’s stock after selling 37,504 shares during the period. Systematic Financial Management LP owned about 3.27% of Enhabit worth $14,620,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of EHAB. SummerHaven Investment Management LLC grew its holdings in Enhabit by 2.8% during the second quarter. SummerHaven Investment Management LLC now owns 61,508 shares of the company’s stock valued at $549,000 after purchasing an additional 1,660 shares during the period. Oppenheimer & Co. Inc. grew its stake in shares of Enhabit by 7.2% during the 1st quarter. Oppenheimer & Co. Inc. now owns 26,224 shares of the company’s stock worth $306,000 after acquiring an additional 1,768 shares during the period. PNC Financial Services Group Inc. increased its holdings in Enhabit by 13.2% in the 4th quarter. PNC Financial Services Group Inc. now owns 16,058 shares of the company’s stock worth $166,000 after acquiring an additional 1,875 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Enhabit by 5.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 37,950 shares of the company’s stock valued at $443,000 after acquiring an additional 2,078 shares during the period. Finally, Illinois Municipal Retirement Fund lifted its holdings in Enhabit by 10.7% during the first quarter. Illinois Municipal Retirement Fund now owns 33,042 shares of the company’s stock valued at $385,000 after purchasing an additional 3,193 shares during the last quarter.

Insider Buying and Selling

In related news, Director Jeffrey Bolton bought 5,000 shares of the company’s stock in a transaction on Thursday, August 22nd. The stock was acquired at an average cost of $8.01 per share, for a total transaction of $40,050.00. Following the completion of the transaction, the director now directly owns 78,877 shares in the company, valued at approximately $631,804.77. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 1.90% of the stock is owned by company insiders.

Enhabit Price Performance

EHAB opened at $7.93 on Friday. The firm has a market capitalization of $398.72 million, a P/E ratio of -4.78 and a beta of 1.82. Enhabit, Inc. has a one year low of $7.12 and a one year high of $12.13. The company has a fifty day moving average price of $8.60 and a 200-day moving average price of $9.32. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.48 and a quick ratio of 1.48.

Enhabit (NYSE:EHAB) last posted its earnings results on Tuesday, August 6th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.05 by $0.02. Enhabit had a positive return on equity of 1.61% and a negative net margin of 0.84%. The business had revenue of $260.60 million during the quarter, compared to analysts’ expectations of $265.99 million. During the same period in the previous year, the business earned $0.04 earnings per share. Equities research analysts expect that Enhabit, Inc. will post 0.26 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Bank of America dropped their target price on Enhabit from $9.00 to $8.00 and set an “underperform” rating on the stock in a research report on Thursday, June 27th. One investment analyst has rated the stock with a sell rating and six have given a hold rating to the company. Based on data from MarketBeat, Enhabit presently has an average rating of “Hold” and an average price target of $9.35.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.